StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research report released on Thursday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Up 1.0 %
Shares of EVOK opened at $5.25 on Thursday. The company’s 50 day simple moving average is $4.80 and its 200-day simple moving average is $5.71. Evoke Pharma has a 12-month low of $3.54 and a 12-month high of $17.88. The firm has a market cap of $45.13 million, a PE ratio of -2.87 and a beta of 0.39.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%. The business had revenue of $2.55 million during the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
- Five stocks we like better than Evoke Pharma
- Dividend Payout Ratio Calculator
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- How to invest in marijuana stocks in 7 steps
- MarketBeat Week in Review – 9/30 – 10/4
- What Do S&P 500 Stocks Tell Investors About the Market?
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
